Revenue Recognition (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Jul. 31, 2021	Feb. 28, 2019	Mar. 31, 2021	Jun. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	May 31, 2021	Aug. 31, 2019
Deferred revenue, Long-term					$ 21,318	$ 22,805
Other assets					18,820	14,743
Deferred revenue					28,722	72,930
Deferred revenue, current portion					7,404	50,125
Total revenues					625,486	391,005	$ 302,328
Deferred revenue, long-term portion					21,318	22,805
Revenue recognized during the period that was included in deferred revenues at the beginning of the period					37,784
Product
Revenue recognized					5,700	5,400	2,400
Cost of revenues					302,663	185,865	162,604
Total revenues					567,149	367,211	269,881
Licensing and other
Cost of revenues					15,755	17,755	12,866
Total revenues					58,337	$ 23,794	32,447
Genetic testing services and provision of IVD kits
Revenue recognized during the period that was included in deferred revenues at the beginning of the period					300
Qiagen
Proceeds from license agreement								$ 5,000
Agreement term						10 years
Revenue, remaining performance obligation								40,000
Revenue recognized during the period that was included in deferred revenues at the beginning of the period					28,600
Qiagen | Volume, regulatory and commercial milestones
Revenue, remaining performance obligation								$ 10,000
Qiagen | Other licensing and other revenue
Refunds of revenues previously deferred			$ 10,000
Deferred revenue			$ 28,600
BGI Genomics
Proceeds from license agreement		$ 50,000		$ 35,600
Receivable				2,500
Deferred revenue, Long-term					20,400
Deferred revenue, current portion					3,200
Deferred revenue, long-term portion					20,400
BGI Genomics | Sequencing services
Other assets				6,000
BGI Genomics | Sequencing products
Other assets				4,000
BGI Genomics | Sequencing products and services
Other assets				$ 10,000
Foundation Medicine ("FMI")
Proceeds from license agreement							16,300
Agreement term						5 years
Automatic renewals, successive period thereafter						1 year
Deferred revenue, Long-term					900
Deferred revenue, current portion					500
Deferred revenue, long-term portion					900
Foundation Medicine ("FMI") | Milestone payments
Proceeds from license agreement	$ 1,000
Deferred revenue, current portion					$ 2,000				$ 1,000
Foundation Medicine ("FMI") | Upfront licensing fees and prepaid revenues
Initial transaction price										$ 13,300
Foundation Medicine ("FMI") | Developmental, regulatory, and commercial milestones
Initial transaction price										$ 32,000
Foundation Medicine ("FMI") | Developmental performance milestones
Proceeds from license agreement							3,000
Foundation Medicine ("FMI") | Licensing fees and prepaid revenue
Proceeds from license agreement							$ 13,300